Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study
Published Online: 2020-03-?
Journal: The Lancet Haematology•Publisher: Elsevier BV
Authors: Aleksander Skotnicki•Alexander Myasnikov•Andrei Cucuianu•Anna Vallova•Antonia Hatalova•Arpad Illes•Barbara Grohmann-Izay•Carlos Besses Raebel•Christoph Klade•Delia Monica Dima•Dominik Wolf•Dorota Krochmalczyk•Elena Volodicheva•Ella Willenbacher•Emanuil Gheorghita•Emilie Cayssials-Caylus•Ernst Forjan•Franz Bauer•Georgi Mihaylov•Halyna Pylypenko•Hans C Hasselbalch•Heinz Gisslinger•Horia Bumbea•Irina Sokolova•Janos Jakucs•Jean-Jacques Kiladjian•Jerome Rey•Jiri Mayer•Jiri Schwarz•Jolanta Starzak-Gwozdz•Jose Miguel Torregrosa-Diaz•Krzysztof Warzocha•Kurt Krejcy•Liana Gercheva-Kyuchukova•Lydia Roy•Lylia Sivcheva•Malgorzata Calbecka•Maria Soroka-Wojtaszko•Mario Cazzola•Mathieu Puyade•Mihaela Lazaroiu•Miklos Egyed•Mikulas Hrubisko•Nicoleta Berbec•Olga Cerna•Pencho Georgiev•Petr Dulicek•Polina Kaplan•Richard Greil•Robert Kralovics•Sergiy Klymenko•Steffen Koschmieder•Tamas Masszi•Tamila Lysa•Uwe Platzbecker•Vera Stoeva•Vera Yablokova•Veronika Buxhofer-Ausch•Viktor Rossiev•Zita Borbenyi•Zvenyslava Masliak
